Home
About Us
Conditions & Procedures
Conditions
Procedures
Faculty
Patient Resources
Research
News & Events
Make a Gift
A gift to the UCSF Department of Surgery can help physicians and scientist find treatments and cures for serious liver diseases such as hepatitis B & C, and liver cancer.
Peter G. Stock, M.D., Ph.D.
Professor of Surgery
Surgical Director, Pancreas Transplant Program
Surgical Director, Pediatric Renal Transplant Program
Co-Director, Pancreatic Islet Cell Transplant Program
Contact Information
(415) 353-8617
peter.stock@ucsfmedctr.org
Appointments
(415) 353-1888 Liver
(415) 353-1551 Kidney and Pancreas
BiographyEducation
- University of Illinois, Urbana, IL, B.S., Biology, 1974-78
- University of Illinois, Chicago, IL, M.D., Medicine, 1978-82
- University of Minnesota, Minneapolis, MN, Ph.D., Surgery, 1985-92
Residencies
- University of Minnesota, Intern, General Surgery, 1982-83
- University of Minnesota, Resident, General Surgery, 1983-90
Fellowships
- University of California, San Francisco, Fellow, Transplant Surgery, 1990-92
Board Certification
- American Board of Surgery, 1991
Clinical Expertise
- Bile Duct Injuries
- Bile Duct Strictures
- Cholangiocarcinoma (Bile Duct Cancer)
- Choledochal Cyst Disease
- Dialysis Access
- End-Stage Kidney Disease
- Fulminant Hepatic Failure
- Hepatitis B
- Hepatitis C
- Hepatocellular Carcinoma (Liver Cancer)
- Kidney and LIver Transplantation in HIV Patients
- Kidney Transplantation
- Liver Transplantation
- Living Donor Kidney Transplantation
- Living Donor Liver Transplantation
- Pancreas Transplantation
- Pancreatic Islet Cell Transplantation
- Pediatric Kidney Transplantation
- Pediatric Liver Transplantation
- Polycystic Kidney Disease
- Polycystic Liver Disease
- Portal Hypertension
Biography
Peter G. Stock, M.D., Ph.D. is Professor of Surgery at UCSF, Surgical Director of the Pediatric Renal Transplantation Program and Surgical Director of the Pancreas Transplant Program. He was trained at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992.
Highly respected by his peers, Dr. Stock was named to the list of U.S. News "Top Doctors," which denotes the top 10% of physicians within a region practicing a given specialty. He is a frequent presenter on issues related to transplantation and immunosuppression, and holds membership in numerous professional and honorary societies. Dr. Stock specializes in liver, kidney and pancreas transplantation.
Research Summary
Dr. Stock's current basic science research interests include the induction of transplantation tolerance to block both alloimmunity as well as recurrent autoimmunity following pancreatic islet transplantation. Rresults from these studies can be directly applied to the protection of human pancreatic islets following transplantation into diabetic recipients.
Dr. Stock also conducts research on the safety and efficacy of solid organ transplantation in people with HIV. With the advent of highly active anti-retroviral therapy (HAART), people are no longer dying from progression of HIV to AIDS, but rather as result of the co-morbidities associated with HIV infection.
Dr. Stock is Principal Investigator on an NIH-sponsored national multicenter trial examining the impact of HIV on graft survival, the impact of immunosuppression of the immune response against HIV and co-pathogens (HBV, HCV, HPV, CMV, EBV), and the pharmacokinetic interactions of immunosuppressive agents and HAART therapy. Recently, the group reported in the New England Journal of Medicine (see below), that HIV kidney transplant recipients have survival similar to other patients undergoing kidney transplants. These studies will have a direct impact on the management of a rapidly increasing number of HIV-infected patients with end stage liver disease secondary to hepatitis B and C co-infection.
Clinical Trials
Selected Publications
- Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of Kidney Transplantation in HIV-Infected Recipients. N Engl J Med. 2010 Nov 18;363(21):2004-2014. PubMed PMID: 21083386.
- Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet Transplantation in Type 1 Diabetic Patients Using Calcineurin Inhibitor-Free Immunosuppressive Protocols Based on T-Cell Adhesion or Costimulation Blockade. Transplantation. 2010 Oct 26. [Epub ahead of print] PubMed PMID: 20978464.
- Wiseman AC, Wainright JL, Sleeman E, McBride MA, Baker T, Samana C, Stock P. An analysis of the lack of donor pancreas utilization from younger adult organ donors. Transplantation. 2010 Sep 15;90(5):475-80. Review. PubMed PMID: 20595930.
- Mukhtar RA, Baskin LS, Stock PG, Lee H. Long-term survival and renal transplantation in a monozygotic twin with cloacal dysgenesis sequence. J Pediatr Surg. 2009 Dec;44(12):e31-3. PubMed PMID: 20006002.
- Tan-Tam CC, Frassetto LA, Stock PG. Liver and kidney transplantation in HIV-infected patients. AIDS Rev. 2009 Oct-Dec;11(4):190-204. Review. PubMed PMID: 19940946.
In the News
Twenty-Five Department of Surgery Faculty Named to U.S. News “Top Doctors†List
U.S. News - Mar 01, 2012In its most recent survey, U.S. News in collaboration with Castle Connolly Medical Ltd. listed twenty-five (25) surgeons in the UCSF Department of Surgery, nearly one-third (1/3) of the clinical faculty, on the list of U.S. News "Top Doctors". The list, compiled from the opinion of colleagues, denotes the top 10% of physicians within a region practicing a given specialty. Fifteen of the 25 department surgeons were also named by their peers to the list of America's Top Doctors (ATD), a distinction reserved for the top 1% of physicians in the nation for that specialty. The listings are published online at U.S. News. The group rankings are intended to guide patients in selecting a doctor and physicians in making specialty referrals.
UCSF Study Prompts Calls to Repeal Ban on Transplanted Organs from HIV-Positive Donors
New York Times - Apr 11, 2011Last year, a team led by Dr. Peter Stock of UCSF reported on results from a large multicenter study testing the safety and feasibility of transplanting kidneys where both the donor and recipients were infected with HIV, the virus that causes AIDS. The results, reported in the New England Journal of Medicine, showed that the recipients survived nearly as long as non-HIV infected recipients of kidney transplants. As a result of the Stock-led trial, and a just-published paper from Johns Hopkins projecting that 500 to 600 H.I.V.-infected livers and kidneys would become available each year if the ban were repealed, the paradigm appears to be changing. Federal health agencies, including the CDC, are now urging, as reported by the N.Y. Times in today's editions, that the absolute ban on transplanting H.I.V.-positive organs be lifted.
UCSF Liver Transplant Team Shares Expertise in Latin America
UCSF News Office - Mar 23, 2011"Previously, Uruguay had tried to go it alone, but high mortality rates soon caused doctors to shut the program down. After their initial visit, the UCSF transplant team, including anesthesiologist Claus Niemann, MD (pictured first), and surgeons Ryutaro Hirose, MD (pictured second), and Peter Stock, MD, PhD, (pictured third) continued to consult with the team in Uruguay, guiding them through everything from patient selection procedures to the use of immunosuppressive medications following surgery. When it came time for Uruguayan doctors to conduct their first liver transplant since revamping the program, UCSF doctors oversaw the operation by dialing in via Skype."
Kidney Transplants Found Safe in HIV Patients
BOSTON (Reuters) - Nov 18, 2010"People infected with the AIDS virus can safely receive a kidney transplant, researchers reported on Wednesday. The finding, published in Thursday's New England Journal of Medicine, is good news for people with HIV who are more prone to kidney disease, in part because of the drugs they must take to stay healthy. Before drug cocktails turned HIV from a death sentence to a chronic condition, patients were not eligible to receive a kidney. But now they can. 'Patient and graft survival are really pretty good and it approximates the general population,' Dr. Peter Stock of the University of California San Francisco, who led the study, said in a telephone interview."
Improving the outlook for simultaneous pancreas-kidney transplants
UCSF Diabetes Center - San Francisco, CA - Feb 01, 2005"The body's rejection of transplanted organs and tissues is an unfortunate risk of transplant surgery. Historically, rejection rates in a simultaneous pancreas-kidney (SPK) transplant have been as high as 80% and, in 2001, averaged nearly 20%. ........Diabetes Center surgeons Peter Stock, (left) and Chris Freise (right) have been pioneering new methods of immunosuppression for SPK transplants that do not rely upon steroids, with great success...... "
